vitro, the most active of these inhibitors, P4 (DL-threo-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol), was found to exhibit IC 50 s against human cancer cell lines comparable in effectiveness to several clinically used agents (Abe et al, 1995) , suggesting that GSLs play a constitutive role in tumour cell growth and differentiation and thus are potentially useful targets for effective cancer therapy.
Multi-drug resistant (MDR) tumour cells have been shown to be especially sensitive to the growth-inhibiting activity of PDMP (Rosenwald and Pagano, 1994) and the MDR effect has been shown to be reversed by another P-drug (Lavie et al, 1996) . In vivo, GSL synthase inhibitors were found to be both well tolerated and to effectively limit tumour growth (Inokuchi et al, 1987 (Inokuchi et al, , 1990 Nakagawa et al, 1998) .
The present study was designed to identify functional and phenotypic alterations induced by the GSL synthase inhibitor, P4, on 5T33 murine myeloma cells. This cell line serves as a wellcharacterized animal model of human multiple myeloma (Radl et al, 1988; Manning et al, 1992) . Multiple myeloma is an incurable B-cell malignancy which accounts for >20% of all human haematological cancers (Greipp, 1992) . Although new treatment regimens incorporating bone marrow transplantation achieve 5 times higher complete remission rates and prolonged overall survival compared to conventional therapy, i.e. melphalan and prednisolone, relapse due to residual disease is inevitable, with a median survival of 36 months (Cremer et al, 1997) . The effects of Effects of the glucolipid synthase inhibitor, P4, on functional and phenotypic parameters of murine myeloma cells
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P4 on cell growth, metabolism, clonogenicity and antigen expression were determined in vitro prior to conducting in vivo studies addressing the therapeutic efficacy and immunization potential of this inhibitor in mice.
The results reported below demonstrate the cytotoxic and cytostatic potential of P4 in this system.
MATERIALS AND METHODS

5T33 murine multiple myeloma cell line
The cells were maintained in RPMI-1640 medium (Flow Laboratories, Irvine, UK) containing 10% fetal calf serum (FCS; Gibco, Gaithersburg, MD, USA), 2 mM L-glutamine, 100 mM sodium pyruvate, 100 mM non-essential amino acids, penicillin sodium salt (5000 U ml -1 )/streptomycin sulphate (5 mg ml -1 ) (Trace Biosciences, Castle Hill, NSW, Australia), and 50 µM 2-mercaptoethanol as previously described (Manning et al, 1992) . All cells were shown to be free of Mycoplasma by the polymerase chain reaction (PCR) assay.
P4
The inhibitor was from Matreya, Inc. (Pleasant Gap, PA, USA). It was stored as a 5 mM stock solution in sterile, fatty acid-poor bovine serum albumin (BSA)/saline (molar ratio of 5:1, P4:BSA).
MTT assay
3-(4,5-dimethylthiazo-2-YL)-2,5-diphenyltetrazolium bromide (MTT) was from Sigma Chemical Co. (St Louis, MO, USA) and the metabolic assay was performed according to the method of Mosmann (1983) . Briefly, 2.5 × 10 4 tumour cells in 0.1 ml were incubated overnight in 96-well, flat-bottomed microtitre plates (Disposable Products Pty Ltd., Adelaide, SA, Australia) and then exposed to 0-12 µM P4 (total volume 0.2 ml) for 4 days. The plates were centrifuged (1000 g for 5 min) and 0.1 ml of the supernatant was removed. An aliquot of 30 µl of MTT in phosphatebuffered saline (PBS) (5 mg ml -1 ) was added to each well and the plates were incubated at 37°C for 4-6 h. Extraction buffer (15% sodium dodecyl sulphate (SDS) in 50% v/v sterile water: dimethylformamide; pH 4.7; 0.1 ml) was then added to each well and the plates were incubated overnight at 37°C. Absorbances were determined at 595 nm using a BioRad Model 450 microplate reader (Hercules, CA, USA). They were shown to be directly proportional to cell numbers, achieving an R 2 of 0.994 over a range of 250-50 000 5T33 myeloma cells well -1 (Manning et al, 1995) . The P4 concentrations required to inhibit tumour cell growth by 50% (EC 50 ) and by 90% (EC 90 ) were determined from the linear portion of the growth inhibition curve (Figure 1) .
To assess the recovery of myeloma cell growth following P4 exposure, the cells were first incubated with 0-4 µM P4 in 75 cm 2 tissue culture flasks (Corning Costar Corp., Cambridge, MA, USA) for 3 days, then washed and counted by haemacytometer. Viability was checked by trypan blue exclusion. Viable cells (2.5 × 10 4 well -1 ) were then seeded into 96-well microtitre plates and assessed for proliferation by virtue of their metabolic activity after 5 days in inhibitor-free medium, using the MTT assay as described above (Manning et al, 1995) .
Methylcellulose assay
To assess the clonogenic potential of P4-treated cells, the cells were treated as above and diluted to 300 cells ml -1 in 2× Dulbecco's modified Eagles medium (DMEM; Flow Labs.) containing 20% FCS. Methylcellulose (Fluka Methocel 65HG, Buchs, Switzerland) was prepared as described by Klinken (1988) . Equal volumes of cell suspension and methylcellulose solution (at 37°C) were mixed and 2 ml aliquots were added to triplicate wells of a 24-well plate (Costar). Colonies were counted after incubation at 37°C for 12-14 days.
Apoptosis detection
Cells were treated with 0-4 µM P4 for 3 days at 37°C, washed, counted and the apoptotic cells detected by virtue of their ability to bind annexin V and exclude propidium iodide (PI). These assays were performed using an R&D Systems Apoptosis Detection Kit (Minneapolis, MN, USA) following the manufacturer's instructions. Cells were analysed using a Coulter EPICS XL-MCL (Flow Cytometry Section, Division of Laboratory Medicine, Royal Perth Hospital) with gates set at 10 1 log fluorescence for PI and 10 2 log fluorescence for fluorescein isothiocyanate (FITC)-annexin V. Five thousand cells were counted for each sample. The data are presented as the percent viable (unstained) cells, cells undergoing necrosis (stained with both FITC-annexin V and PI) or cells undergoing apoptosis (stained with FITC-annexin V only).
Phenotypic analysis
The effects of P4 on cell surface expression of differentiation antigens (H-2 Class I, H-2 Class II and CD45), adhesion molecules (CD44 and CD54) and the IgG 2b paraprotein were examined by incubating the cells with 0-4 µM P4 for 3 days, and assessing surface antigen expression using optimum concentrations (determined by titration) of the following antibodies: mouse anti-mouse H-2 pan Class I (kindly provided by Dr P Price, Department of Immunology, Royal Perth Hospital, Perth, WA, Australia), rat antimouse H-2 I-A and rat anti-mouse CD45 (both from Serotec Ltd., Oxford, UK), rat anti-mouse CD44 and rat anti-mouse ICAM-1 (CD54) (both from R&D Systems), and rat anti-mouse IgG 2b (Biosource Int., Camarillo, CA, USA). Antibody binding was detected using a biotinylated goat F(ab´) 2 anti-rat Ig followed by a streptavidin-fluorescein conjugate (both obtained from Biosource). For each sample, 10 000 cells were analysed using the Coulter EPICS.
Statistical analysis
Data were analysed using the two-tailed, paired Student's t-test and are presented as the mean ± standard deviation (s.d.) or standard error of the mean (s.e.m.).
RESULTS
Inhibition of 5T33 myeloma cell growth by P4
P4 effectively inhibited cell growth, demonstrating an IC 50 of 3.9 ± 0.3 µM for 20 experiments. A representative growth inhibition curve is shown in Figure 1 . Growth inhibition of the cells occurred over a small P4 concentration range, with the IC 90 achieved at only slightly higher concentration than the IC 50 , i.e. 7.1 ± 0.3 µM.
Kinetics of P4-induced growth inhibition
Significant growth inhibition was achieved by incubating cells in the presence of only 1 µM P4 (Figure 2 ). Viable cell recovery was reduced from 18 ± 2 × 10 6 for untreated cells to 1.5 ± 0.1 × 10 6 for cells exposed to 4 µM P4 for 3 days (92% reduction). These remaining cells represent only 50% of the starting cell number (i.e. 3 × 10 6 flask -1 ) suggesting that a large proportion of the tumour cells are actually being destroyed by P4. As day 4 control cultures demonstrated reduced cell recovery as compared to day 3, probably due to nutrient and GSL depletion, all remaining experiments were conducted using cells exposed to P4 for 3 days. Table 1 depicts the effects of P4 on various functional parameters essential for tumour growth and development. Inhibition of all parameters tested was found to be dose-dependent with the IC 50 concentration (i.e. 4 µM) reducing functional activities by 45-88%. Both cytostatic and cytotoxic growth inhibition were observed. Significant cytostatic inhibition was observed at the lowest concentration of P4 tested (0.5 µM) with cell recovery and proliferation reduced by 21% and 28% respectively (P < 0.001). In contrast, significant loss of cell viability, indicative of cytotoxic activity, was only achieved at the higher concentrations of P4, 3-4 µM (P < 0.001). Exposure of the cells to 4 µM P4 for 3 days reduced cell viability by 45%. The same concentration decreased cell recovery by 87% (P < 0.001). As shown in Figure 2 , cell recovery following 4 µM P4 treatment was actually 33% less than the starting cell number (2 vs 3 × 10 6 cells; Table 1 ) resulting in a negative proliferation index for these cultures (-0.4). These findings further support direct tumour cell lysis by P4 in addition to its cytostatic activity.
Effects of P4 on 5T33 myeloma cell functional activities
Using metabolic activity as a measure of cell numbers, P4 exposure was found to significantly decrease myeloma cell growth with 4 µM P4 reducing metabolic activity by 58% compared to Cells were incubated for 3 days in the presence of 0-4 µM P4, washed and assessed for functional activity. N = 10 experiments for each parameter. untreated cells (Table 1 ; P < 0.001). The clonogenic potential of the cells was even more sensitive to the inhibitory effects of P4 with exposure to 0.5 µM P4 inducing a 40% decrease in clonogenic potential (from 43 ± 5 to 26 ± 5 colonies well -1 ; P < 0.001). The IC 50 concentration (4 µM) of P4 inhibited colony formation by 86% (P < 0.001).
Induction of apoptosis by P4
The dose-dependent loss of viability observed for P4-treated cells was found to be due both to necrosis and to apoptosis (Figure 3) . At lower concentrations of P4 (0.5-1 µM), the increase in necrotic cells alone (from 4 ± 0.4% to 10 ± 1%) did not significantly decrease cell viability, which supports the viability results shown in Table 1 . However, 15 ± 1% of the cells treated with 0.5 µM P4 were found to be undergoing apoptosis (Figure 3 ). This represents a population of 'non-viable' cells that would not be detected by the trypan blue assay, suggesting that even at low P4 concentrations, a significant number of the cells are programmed for cell death. Cell viability was reduced from 88 ± 1% to 48 ± 1% following exposure to 4 µM P4 for 3 days with 26 ± 2% of the non-viable cells undergoing apoptosis (Figure 3 ; P < 0.001).
Effects of P4 on surface antigen expression
The effects of P4 treatment on expression of cell surface antigens involved in differentiation, adhesion and immunogenicity were evaluated as potential markers of functional alterations. Both the Class I and Class II antigen presentation molecules demonstrated dose-dependent alterations in cell surface expression following incubation with P4 (Table 2) . Myeloma cell exposure to as little as 2 µM P4 was sufficient to reduce the number of cells expressing the Class I antigen from 95 ± 1% to 87 ± 1% (P < 0.001), with 4 µM P4 decreasing this number even further. Surface expression No difference was observed for cells treated with 0.5 or 1 µM P4 so the data have been pooled. *P < 0.001 compared to untreated cells.
of Class I was observed on only 61 ± 4% of cells following treatment with 4 µM P4 (Table 2 ; P < 0.001). In complete contrast, Class II antigen expression was markedly increased by the inhibitor, with 4 µM P4 increasing expression almost tenfold (from 2 ± 0.4% to 14 ± 3%; P < 0.001). Approximately 90% of the cells were found to express the differentiation antigen, CD45, which is a marker for primitive to immature plasma cells/myeloma cells (Schneider et al, 1997) , and this expression was not altered by P4 exposure regardless of the inhibitor concentration (Table 2) .
CD44 has been shown to be an important adhesion molecule for myeloma cell homing to the bone marrow and binding to bone marrow stromal cells, whereas CD54 (ICAM-1) appears to play only a minor role in this aspect of disease development (Okada and Hawley, 1995) . Of interest, P4 was found to induce a striking dosedependent decrease in CD44 expression without altering CD54 expression (Table 2) . Whereas 90 ± 2% of untreated cells expressed CD44, only 38 ± 2% of cells exposed to 4 µM P4 maintained surface expression of this antigen (P < 0.001). ICAM-1 (CD54) expression, on the other hand, was observed on > 90% of all the cells tested regardless of P4 exposure. These results imply an important role for GSLs in CD44 function.
The myeloma paraprotein has been shown to be a highly immunogenic molecule capable of inducing therapeutically effective anti-idiotypic immune responses in both mice and humans (Croese et al, 1991a (Croese et al, , 1991b Kwak et al, 1995) . P4 exposure was found to induce a large, dose-dependent increase in the number of cells expressing IgG 2b (Table 2) . Only 5.6 ± 0.8% of untreated cells expressed the paraprotein on their surface compared to 26.9 ± 3.6% of cells exposed to 4 µM P4 for 3 days (P < 0.001).
DISCUSSION
The pattern of growth inhibition observed for P4 on the 5T33 murine myeloma cells used in this study (Figure 1 ) was similar to those previously reported for this and other 'P-drugs' against five types of human malignancy (Abe et al, 1995) . The 3.9 µM IC 50 P4 concentration is comparable to those reported for the human cell lines (IC 50 s of 0.7-2.6 µM). The IC 90 P4 concentration was less than twice the IC 50 (i.e. 7.1 µM). P4-induced growth inhibition of both the human and murine cell lines was found to occur over a very small concentration range, as indicated by the steep slopes of the growth inhibition curves (Abe et al, 1995;  Figure 1 ). The uniformity of inhibitor activity observed against the various tumour types provides additional evidence that GSLs play a constitutive role in tumour cell growth and differentiation. It also suggests that GSL synthase inhibitors may have a wider therapeutic application than currently used cytotoxic drugs. The fact that P-drugs have been shown to be effective against MDR tumour cells (Rosenwald and Pagano, 1994; Lavie et al, 1996) is of particular interest given that disease relapse due to the emergence of drug-resistant cells remains the leading cause of death of patients with many types of tumours, including multiple myeloma. Because the 5T33 murine myeloma cells do not express surface P-glycoprotein 170 (P-gp170; data not shown), human myeloma cells of known MDR phenotype will be used to address this important issue.
Several tumour cell functions were found to be markedly downregulated at P4 concentrations (0.5-1 µM), which induced only minimal cytotoxicity (Table 1) . A significant reduction in cell recovery following 3 day incubation with P4 was observed at the lowest concentration of P4 tested (0.5 µM), apparently a reflection of a reduction in both cell proliferation and metabolic activity. Clonogenic potential was also significantly reduced by exposure to low-dose P4, whereas tumour cell viability was not altered under these conditions (Table 1 ). Significant loss of tumour cell viability, as determined by trypan blue uptake, was only observed following incubation with 3-4 µM P4 (Table 1) . In fact, cell recovery was reduced by > 33% of starting cell numbers under these conditions suggesting direct cytolysis of a substantial number of tumour cells by high-dose P4. This dose-dependent distinction between reduced cell growth and induced cell death by GSL synthase inhibitors has been previously reported (Inokuchi et al, 1990; Rosenwald and Pagano, 1994; Abe et al, 1995) . It is likely that cells engage in a 'yin and yang' competition, in which the proliferative effects of glucosylceramide oppose the repressive apoptotic effects of its precursor, ceramide.
The impaired growth and clonogenic potential we observed in treated cells even after the cells were transferred to normal medium, may be the result of retention of P4 by the cells. A test with Madin-Darby canine kidney cells showed, by chromatographic analysis and enzyme assay, that P4 does not readily leave P4-treated cells, even when the cells are homogenized and washed (Abe et al, 1996) . This prolonged action would have the advantage of maintaining viable, non-replicating tumour cells as targets for immune activation. It also suggests that frequent dosing of P4 in a cancer-bearing patient may not be necessary to maintain therapeutic efficacy.
This study identified a dose-dependent increase in cells undergoing apoptosis; which may play a significant role in both the reduced tumour cell recovery and viability observed following P4 exposure (Table 1 and Figure 3) . At the lower concentrations of P4 (0.5-1 µM), the increase in necrotic cells alone was not sufficient to significantly reduce tumour cell viability (95% to 89%), which correlates with the previous trypan blue exclusion results (Table  1) . However, a substantial increase in cells undergoing apoptosis was identified by flow cytometry (from 7% to 15%; Figure 3 ). Significant cytotoxicity was observed following cell exposure to 4 µM P4 for 3 days, with necrotic cells increasing to > 23% of the tumour cell population (Figure 3 ). An additional 26% of the cells were programmed for cell death, i.e. undergoing apoptosis, which indirectly supports the concept of inhibitor-induced accumulation of ceramide (Figure 3) . Abe et al (1995) clearly showed ceramide accumulation at this concentration of P4. Overall, the population defined as 'viable' by this assay was reduced to 55% of control cells under these conditions. These results suggest that in addition to being directly toxic to tumour cells, high-dose glucolipid synthase inhibitor therapy effectively limits the growth potential of a substantial number of the 'surviving' cells.
Cell surface GSLs have been implicated as essential molecules in tumour cell attachment, immune evasion and metastatic spread (Inokuchi et al, 1990; Hakomori, 1994; Kannagi, 1997) . In this study, alterations in several cell surface molecules were readily identified following P4 exposure. The proportion of cells expressing surface H-2 Class I antigen was reduced by P4 in a dose-dependent manner (Table 2) . Several inhibitor-induced alterations may be involved in this effect, including disruption of receptor assembly and transport, of anchoring and presentation on the cell surface, or of β-2-microglobulin (β-2M) production, which is essential for Class I antigen expression (Karre, 1993; Radin et al, 1993; Rosenwald and Pagano, 1994) . Although the loss of Class I positive tumour cells may reduce CD8+ cytotoxic T-cell (CTL) recognition and activation, susceptibility to killing by natural killer (NK) cells should be enhanced in this setting since Class I expression is inhibitory to NK cell function (Karre, 1993) . The immunosurveillance role of NK cells is thought to be particularly important in controlling haematological malignancies and circulating metastatic foci (Karre, 1993) .
In contrast to the effect of P4 on Class I expression, the number of cells expressing H-2 Class II was greatly increased following P4 exposure (Table 2 ). Increased expression of Class II has been shown to be a positive prognostic factor in several tumour systems, resulting in effective immune activation and subsequent tumour regression in some cases (Baskar et al, 1995; Cabrera et al, 1995; Armstrong et al, 1997) . Experiments are currently underway that address P4-induced activation of a tumour-specific immune response in 5T33 myeloma-bearing mice.
The common leucocyte antigen, CD45, which has been shown to be most highly expressed on primitive and immature plasma cells and myeloma cells (Schneider et al, 1997) , was not affected by P4 exposure. Taken together, the results suggest that tumour cells utilize GSLs extensively, but selectively, to maximize survival.
In terms of adhesion molecules, Okada and Hawley (1995) have demonstrated that murine myeloma cells, like human myeloma cells, express surface CD44, ICAM-1 (CD54) and VLA-4. In addition, CD44 and VLA-4 were shown to be involved in myeloma cell binding to bone marrow stromal cells (i.e. endothelial cells, fibroblasts and adipocytes) with ICAM-1 only partially involved in binding to bone marrow-derived macrophages. The present study revealed a marked, P4-dependent decrease in cells expressing CD44 (Table 2 ). This response is to be expected based on the observation that CD44 is closely associated with GSL-rich plasma membrane domains (Ilangumaran et al, 1998) , and may have important implications for myeloma development. Hyaluronan, the ligand for CD44, is found in high concentration in bone marrow (Aruffo et al, 1990) and is known to play an important role in tumour homing and metastasis (Sherman et al, 1994) . It is possible that the loss of CD44 expression would not only interfere with tumour seeding in the appropriate micro-environment, i.e. the bone marrow, but would also relegate tumour cells to the circulation and lymphatics, thereby increasing their exposure to the immune system and allowing effective immune activation prior to tumour establishment. Experiments are currently underway in which mice and/or tumour cells are treated with P4 prior to tumour cell inoculation to investigate inhibitor effects on both tumour development and immune induction in vivo.
The myeloma paraprotein has been shown to be a highly immunogenic molecule capable of inducing both tumour-specific anti-idiotypic antibodies as well as activating idiotypic-specific T-cells (Croese et al, 1991a (Croese et al, , 1991b Kwak et al, 1992 Kwak et al, , 1995 Dabadghao et al, 1998) . Here, we report a significant, dosedependent increase in 5T33 myeloma cells expressing surface IgG 2b paraprotein (up to 27%; Table 2 ). Increased expression of this highly immunogenic antigen may enhance immune recognition with subsequent activation of a protective tumour-specific immune response.
The results of this and many other studies strongly suggest that GSL synthase inhibitors have the potential to be a universally effective form of cancer treatment. Given that current therapies are not curative for the majority of human malignancies, alternative forms of treatment need to be developed to improve the prognosis of patients with cancer. It is anticipated that continued investigations of both the therapeutic and immunization potential of GSL synthase inhibitors will clarify the efficacy of these inhibitors as novel therapeutic agents and lend themselves to the development of more effective treatment for patients with cancer.
